AN2 Therapeutics
ANTX
36 hedge funds and large institutions have $92.9M invested in AN2 Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 3 reducing their positions, and 7 closing their positions.
667% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 3
1.37% more ownership
Funds ownership: 48.95% → 50.32% (+1.4%)
5% less funds holding
Funds holding: 38 → 36 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
44% less capital invested
Capital invested by funds: $165M → $92.9M (-$72.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.42M |
| 2 |
BlackRock
New York
|
+$3.44M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$2.9M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$581K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$12.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$767K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$706K |
| 4 |
Renaissance Technologies
New York
|
-$382K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$299K |
ANTX Hedge Fund Activity: Q4 2022 in Review
36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q4 2022, worth a combined $92.9M — down 44% from $165M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ANTX and 5 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 23 added.
The largest buyer was Vanguard Group, adding an estimated $5.42M. The largest seller was Deerfield Management, exiting entirely with an estimated $12.5M sold.
- 36 institutional investors held AN2 Therapeutics (ANTX) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $92.9M of AN2 Therapeutics stock for Q4 2022, down 44% quarter-over-quarter.
- 5 funds opened new AN2 Therapeutics positions in Q4 2022 and 7 closed out, a net change of -2 holders.
- The largest AN2 Therapeutics buyer in Q4 2022 was Vanguard Group, an estimated $5.42M added.
- The largest AN2 Therapeutics seller in Q4 2022 was Deerfield Management, an estimated $12.5M sold.
Based on aggregated 13F filings for Q4 2022.